sheehy

CIRM HIV/AIDS disease team technology makes news

Richmond-based Sangamo BioSciences has been making a lot of news lately with their gene editing technology. Theirs is the technique being used in CIRM'S HIV Disease Team Award to John Zaia at The City of Hope (summarized in this San Francisco Business Journal story).

CIRM sends Patient advocates to international stem cell meeting

Today stem cell scientists and patient advocates are descending on Toronto for the annual meeting of the International Society for Stem Cell Research. Among those registering and preparing for three days of science is Don Reed, who is one of 20 patient advocates who received a CIRM stipend to attend. 

On his blog today, Reed writes about his trip to Toronto and the important role of patient advocates in promoting science:

30th Anniversary of HIV/AIDS, CIRM teams making progress

Thirty years ago the first reports of a mysterious illness began appearing in the media. This illness would eventually become known as AIDS.

CIRM board member Jeff Sheehy recently spoke as part of a KQED Forum radio show about the 30th anniversary of HIV/AIDS. As a long-time AIDS activist, Sheehy has been part of the fight for a cure. In his introduction, Sheehy talked about limitations of the current drug regimen for HIV/AIDS:

Guest blogger Jeff Sheehy - CIRM Grantees Show Progress Towards a “Cure for HIV” in Boston

At the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, two members of CIRM's HIV/AIDS Disease Team led by John Zaia at City of Hope presented new research showing the team's progress toward the clinic.

CIRM Innovation: The Patient Advocate Role -- Guest blogger Jeff Sheehy

Duane Roth, my colleague on the CIRM governing board where he serves as one of the vice-chairs, has just published an article, with the title, "The Third Seat at the Table: An Insider's Perspective on Patient Representatives," in the Hasting's Center Report.
Subscribe to RSS - sheehy

© 2013 California Institute for Regenerative Medicine